Skip to main content
20th International Myeloma Workshop Main banner
Back
    20th International Myeloma Society Annual Meeting

    Oral Abstract Session

    Abstract Session 1: MRD and risk stratification

    Wednesday, September 27, 2023
    5:45 PM – 6:45 PM EEST
    Location: Skalkotas

      Co-Chair(s)

    • Morie Gertz, MD, MACP (he/him/his)

      Division of Hematology, Department of Internal Medicine
      Mayo Clinic
      Rochester, Minnesota, United States

    • Hartmut Goldschmidt, MD

      Head of the GMMG Studygroup, Department of Medicine V
      Department of Medicine V, University Hospital Heidelberg; and National Center for Tumor Diseases (NCT)
      Heidelberg, Germany

    Presentations:

    • 5:45 PM – 5:57 PM EEST
      OA-12: Predictors of unsustained measurable residual disease (MRD) negativity in transplant-eligible multiple myeloma (MM) patients

      Speaker: Camila Guerrero – Clínica Universidad de Navarra, Centro de Investigación Médica Aplicada (CIMA), Instituto de Investigación Sanitaria de Navarra (IDISNA), CIBER-ONC number CB16/12/00369

    • 5:57 PM – 6:09 PM EEST
      OA-37: Optimization of the 20/2/20 risk stratification model for patients with smoldering multiple myeloma through integration of the evolving patterns of monoclonal protein and serum free light chains

      Speaker: Annika Werly – Internal Medicine V, University Hospital Heidelberg, Heidelberg, Germany

    • 6:09 PM – 6:21 PM EEST
      OA-31: Efficacy of Bispecific Antibodies in the Treatment of Extramedullary disease and High risk cytogenetics in Relapsed Multiple Myeloma: A Systematic Review

      Speaker: Charan T R Vegivinti, MD (he/him/his) – Jacobi Medical Center / Albert Einstein College of Medicine

    • 6:21 PM – 6:33 PM EEST
      OA-38: Physical activity interventions to improve functional performance in patients with multiple myeloma

      Speaker: Jens Hillengass, MD, PhD – Roswell Park Comprehensive Cancer Center, Buffalo, NY, USA

    • 6:33 PM – 6:45 PM EEST
      OA-49: Mezigdomide (MEZI) plus dexamethasone (DEX) and bortezomib (BORT) or carfilzomib (CFZ) in patients (pts) with relapsed/refractory multiple myeloma (RRMM): results from the CC-92480-MM-002 trial

      Speaker: Albert Oriol, PhD (he/him/his) – Catalan Institute of Oncology and Josep Carreras Institute, Hospital Germans Trias i Pujol, Badalona, Spain